-- ベンチャー・エナジーと上海申基能源環境技術有限公司は、低炭素船舶燃料の供給強化を目的としたグリーンメタノール調達・供給契約を締結したと、両社は月曜日に発表した。 この契約に基づき、ベンチャー・エナジーは申基能源から、欧州連合(EU)の再生可能エネルギー指令に準拠したISCC EU認証グリーンメタノールを購入する。初回出荷は2026年上半期を予定している。 この燃料は、都市ごみ、作物残渣、家畜糞尿などのバイオマス原料から生産され、ライフサイクル全体での二酸化炭素排出量を大幅に削減するように設計されている。 両社は、この製品がEU排出量取引制度(ETS)やFuelEU海上規制など、厳格化する規制要件への対応を海運事業者に支援することを目的としていると述べた。 ベンチャー・エナジーは、自社の海運ネットワークと香港の地域海事ハブとしての地位を活用し、中国のクリーン燃料生産者と世界の船舶燃料購入者を結びつける計画だ。同社はまた、中国本土の生産拠点からアジア各地のバンカリング港まで、環境に優しい船舶燃料のエンドツーエンドの配送を支援するサプライチェーンサービスを提供する計画だ。 Shenji Energyは、ISCC認証を受けたバイオメタノールと、検証済みのサステナビリティ証明書を提供することで、バリューチェーン全体におけるトレーサビリティを確保すると述べた。 この提携には、バイオガス原料の調達とISCC認証システムに関する協力も含まれており、両社はこれらが再生可能な船舶燃料の標準化されたトレーサビリティのある取引枠組みを支援すると述べている。
Related Articles
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%